FNBT
ALXN

FineMark National Bank & Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

FineMark National Bank & Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-114
Closed -$14K – 1100
2016
Q4 		$14K Hold
114
– – ﹤0.01% 895
2016
Q3 		$14K Sell
114
-169
-60% -$21.8K ﹤0.01% 880
2016
Q2 		$33K Hold
283
– – ﹤0.01% 718
2016
Q1 		$39K Hold
283
– – ﹤0.01% 643
2015
Q4 		$54K Buy
283
+1
+0.4% +$175 0.01% 580
2015
Q3 		$44K Buy
282
+74
+36% +$13.5K 0.01% 656
2015
Q2 		$37K Buy
208
+140
+206% +$24.2K ﹤0.01% 739
2015
Q1 		$12K Buy
68
+10
+17% +$1.81K ﹤0.01% 973
2014
Q4 		$11K Hold
58
– – ﹤0.01% 1017
2014
Q3 		$10K Hold
58
– – ﹤0.01% 1027
2014
Q2 		$9K Hold
58
– – ﹤0.01% 1062
2014
Q1 		$9K Sell
58
-106
-65% -$16.9K ﹤0.01% 1075
2013
Q4 		$22K Hold
164
– – ﹤0.01% 813
2013
Q3 		$20K Buy
164
+82
+100% +$9K 0.01% 811
2013
Q2 		$8K Buy
+82
New +$7.9K ﹤0.01% 1015

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FineMark National Bank & Trust's ALXN Position: Q1 2017 in Review

FineMark National Bank & Trust sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 114 shares — an estimated $14K sold.

FineMark National Bank & Trust first reported a position in ALXN in Q2 2013 and held it in 15 quarters. The position peaked at $54K in Q4 2015. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • FineMark National Bank & Trust reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • FineMark National Bank & Trust sold 114 Alexion Pharmaceuticals shares in Q1 2017, an estimated $14K.
  • FineMark National Bank & Trust first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • FineMark National Bank & Trust's Alexion Pharmaceuticals position peaked at $54K in Q4 2015.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on FineMark National Bank & Trust's 13F filing for Q1 2017, filed 12 May 2017.